Réglementé
Revente anticipée
- Niveau de risque
- Très élevé
- Risque-rendement
- Moyen
- Dès
- €500
Financement clôturé le 20 Sep 2026. La page reste en ligne à titre d'information ; des projets ouverts similaires figurent ci-dessous.
Kairos Discovery
France
A Lyon-based biotech developing KDX-350, an oral bivalent CK2 inhibitor for colorectal and clear-cell renal cancer, to license to a pharmaceutical partner from 2027.
Chiffres clés
- Rendement estimé
- jusqu'à 20×
- estimation de la plateforme
- Valorisation
- €3,294,118
- Part proposée
- 21
- Sortie prévue
- 2030
- Fin du financement
- 20 Sep 2026
- Dès
- €1,000
- Objectif
- €850,000
Ce que vous possédez, comment cela peut rapporter, et quand
Qu'est-ce que je possède ?
21 de la société
Consultez les documents pour savoir comment les parts sont détenues et quels droits elles confèrent.
Comment cela peut-il rapporter ?
La plateforme estime jusqu'à 20×
En général, uniquement si la société est vendue ou cotée en bourse. Les estimations sont des affirmations de la plateforme elle-même.
Quand pourrais-je toucher de l'argent ?
Vers 2030
Uniquement en cas de vente ou d'introduction en bourse ; d'ici là, les parts sont difficiles à vendre.
Capital à risque. La plupart des startups échouent ; les estimations sont des affirmations de la plateforme elle-même. Les parts sont difficiles à revendre avant une sortie.
L'IA investirait-elle ?
IA 63 MoyenNotre IA attribue à ce projet 63 sur 100 : Moyen. Comment fonctionne le score IA
Information, et non conseil en investissement personnalisé. Le score IA évalue les documents publiés par la plateforme, peut se tromper et ne prédit pas les rendements.
Analyse IA
IAKairos Discovery — Crowdfunding Investor Memo
A French laboratory company designing an experimental cancer medicine that it plans to sell or license to a large pharmaceutical company rather than sell to patients itself.
Sector: Biotechnology (preclinical oncology) · Stage: Seed (preclinical) · HQ: Lyon, France · Raise: €850,000 target (maximum €1,500,000)
Snapshot
|
1 · Is the price fair? 💶 |
5 / 5 — Supported. At €2.8M–€3.3M before this round, the price is below every European early-stage benchmark we located: a median of €5.0M in Q3 2025 and €3.6M over the longer term (PitchBook-derived data, November 2025), a typical seed range of €4M–€12M (Startkeel, 2026), and a European early-stage median of $6.54M for 2020–2025 (Equidam, Q3 2025). |
|
2 · Can they reach an exit stage? ⭐ |
AI SCORE 63 / 100 — Average The strongest evidence is the people and the science: the chairman led a comparable Lyon company to an acquisition by Eli Lilly in 2023, and the underlying research is published in a peer-reviewed chemistry journal with a crystal structure deposited in a public database. The biggest gap is that the medicine being offered here, KDX-350, is not the compound described in that publication, and no data on KDX-350 itself is in the pack we reviewed. |
|
3 · If they do, what could it pay? 🎯 |
Target 20x over 3.5–4.5 years (the company's own plan; the standard expectation for a seed-stage company is about 10x over 5–7 years). If reached, illustratively 5x–50x before fees and before future dilution. Method: the required sale value divided by the €4.09M value of the whole company at this round's price. The low end is a licensing deal at the median upfront payment for a preclinical cancer drug, $22M (Ambrosia Ventures deal database, 2026); the high end is the company's own stated target of more than €200M once the medicine has shown early results in patients. |
How to read the score
|
85–100 · Excellent |
All key preconditions for reaching an exit stage are evidenced and strong — rare at this stage |
|
70–84 · Good |
Preconditions largely in place, with specific gaps — named in the questions section |
|
50–69 · Average |
Meaningful preconditions missing or weakly evidenced |
|
30–49 · Weak |
Several core preconditions absent, or the evidence points against them |
|
1–29 · Critical |
Fundamental preconditions are not visible in the evidence |
|
What we could check. We checked 33 of the company's claims against public sources. The company registration, its 2023 fundraise, the chairman's previous sale of a business to Eli Lilly, the patent family, the peer-reviewed publication and the French tax ruling all check out against public records. The figures for the medicine itself (KDX-350), the letter of interest from a pharmaceutical company, the current cash position and most of the market-size numbers rest on the company's own materials — see the questions section. Your money is locked in. Crowdfunding shares normally cannot be sold early — expect your money to be tied up for several years, until the company is sold or a similar event happens. |
Three answers, one honest note. The fairness score says whether the entry price is supported by the sector benchmarks we could find. The AI Score is our read on whether the company has the building blocks in place to reach a point where a sale or licensing deal can happen — it audits readiness on the evidence disclosed. It is not a measure of how likely success is, and even companies with every building block in place fail more often than they succeed, which is why this kind of investing only works as a small part of a spread-out portfolio. The returns range is an illustration built from named industry benchmarks, not a forecast. Where something was not in the pack we reviewed, it did not lower any score — it appears in the questions list instead, so you can ask the company directly before you invest. The listing was reviewed by a licensed crowdfunding platform before it went live. Nothing here is a recommendation.
At a glance
|
✅ Three reasons to look closer |
⚠️ Three reasons for caution |
|
|
|
Deal terms. No terms were identified in the reviewed documents that would prevent a crowdfund investor from sharing in the upside. Full mechanics are at the end of this memo. One point to check: the two platform documents disagree on a single right. The official Key Investment Information Sheet states there is no prio… |
L'analyse complète couvre l'emprunteur ou l'entreprise, la garantie, les flux de trésorerie, les risques et un verdict. Connectez-vous pour la lire.
Information, et non conseil en investissement personnalisé. Le score IA évalue les documents publiés par la plateforme, peut se tromper et ne prédit pas les rendements.
Interroger l'IA sur ce projet
Connectez-vous pour interroger l'IA sur les documents de ce projet.
ConnexionCe projet vous plaît ?
👍 Oui · 0 👎 Non · 0
Commentaires · 0
- Pas encore de commentaires.
La plateforme et des projets similaires
Proposé sur
Projets ouverts similaires
Kepplair Evolution
Sowefund
- Rendement estimé
- jusqu'à 7×
- estimation de la plateforme
- Valorisation
- €60,000,000
Objectif : €9m
Dès €500
Voir le projet
Wind Fisher
Sowefund
- Rendement estimé
- jusqu'à 10×
- estimation de la plateforme
- Valorisation
- €9,961,800
Objectif : €600k
Dès €1,000
Voir le projet
Blumana
Sowefund
- Rendement estimé
- jusqu'à 28×
- estimation de la plateforme
- Valorisation
- €2,799,571
Objectif : €750k
Dès €1,000
Voir le projet